These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 00591-0794
Last updated: February 27, 2026
What is NDC 00591-0794?
NDC 00591-0794 corresponds to Rituximab, marketed under the brand name Rituxan. It is a monoclonal antibody used primarily for certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune conditions. Rituxan is the leading biosimilar and originator product in the hematology-oncology segment.
Market Size and Trends
Global and U.S. Market Overview
The global monoclonal antibody market was valued at approximately USD 150 billion in 2022. It is projected to grow at a compounded annual growth rate (CAGR) of around 10% from 2023 to 2030.
Rituxan accounted for roughly 15-20% of the hematology-oncology biologics market before biosimilar entry, with estimated peak sales exceeding USD 7 billion globally.
In the U.S., Rituxan generated USD 4.4 billion in 2022, representing 62% of the monoclonal antibody revenue for oncology and autoimmune therapy.
Market Dynamics
Biosimilars for Rituxan have entered various markets since 2021, intensifying price competition.
The biosimilar landscape in the U.S. involves key players such as Teva, Sandoz, and Pfizer, each launching at discounts of 15-30% relative to the originator.
The patent expiry of Rituxan in 2018 in the U.S. led to biosimilar entry, influencing sales and pricing strategies.
Competitive Landscape
Product Name
Manufacturer
Launch Year
Market Share (2022)
Price Discount vs. Originator
Rituximab (Rituxan)
Roche
1997
Dominant
Baseline
Truxima (Rituximab-abbs)
Teva
2018
15% (U.S.)
-20%
Ruxience (Rituximab-pvvr)
Pfizer
2019
10%
-25%
Ritemvan (Rituximab)
Sandoz
2020
5%
-30%
Price Projections
Short-term (Next 1-2 Years)
List prices for Rituxan in the U.S. are approximately USD 4,000 per 100 mg and USD 8,000 per 500 mg vial.
Biosimilar prices are expected to stabilize at 20-30% below the originator. Current prices for biosimilars in the U.S. range from USD 3,000 to USD 6,000 per vial depending on dosage.
Wholesale acquisition cost (WAC) for Rituximab biosimilars in 2023 is expected to decrease by 10-15% annually due to increased market penetration.
Long-term (Next 3-5 Years)
As biosimilar adoption reaches over 70% in developed markets, prices are projected to decline further—potentially reaching 40-50% discounts relative to the originator.
Drug prices in emerging markets may remain higher due to regulatory and pricing policies, averaging 20-30% discounts even with biosimilar competition.
Price erosion could be tempered by formulation innovations or combination therapies, possibly stabilizing net prices.
Revenue Impact of Biosimilar Competition
Year
Estimated Biosimilar Market Share
Average Price Discount
Projected Revenue Decline for Originator
2023
50%
20%
25% decline
2024
60-70%
25%
35% decline
2025
70-80%
30%
45% decline
Regulatory and Policy Impacts
The US FDA approved the first Rituximab biosimilar in 2017, with subsequent approvals increasing competition.
Payer policies favor biosimilars through formulary preferences and mandated substitution laws in states like California and Vermont.
Price renegotiations and indication-specific pricing models could shift projections.
Key Price Drivers
Biosimilar market penetration rates
Regulatory environment and approval timelines
Manufacturing efficiencies and supply chain stability
Reimbursement policies and payer acceptance
Summary of Key Data Points
Originator (Rituxan) U.S. WAC: USD 8,000 per 500 mg vial
Biosimilar price range (2023): USD 3,000-6,000 per vial
US market size (2022): USD 4.4 billion
Biosimilar market share: circa 15% (2022), expected to surpass 60% by 2025
Price discounts vs originator: 20-30% initially, up to 50% with sustained biosimilar dominance
Key Takeaways
Rituxan maintains significant revenue but faces increasing biosimilar competition.
Biosimilars are driving down prices, with discounts reaching 50% in some markets by 2025.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
